Form 4: Protara Therapeutics Executive Sells Shares to Cover Tax Obligations

Jacqueline Zummo, Chief Scientific Operations Officer at Protara Therapeutics, sold 2,157 shares to cover income tax obligations related to a previously granted stock award.

Summary

• Jacqueline Zummo, the Chief Scientific Operations Officer of Protara Therapeutics, sold 2,157 shares of common stock on January 3, 2025.
• The sale was executed to cover income tax obligations arising from the vesting of a Restricted Stock Unit Award granted on January 3, 2022.
• The shares were sold at a price of $6.14 per share.
• Following the transaction, Ms. Zummo directly owns 102,139 shares of Protara Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction related to executive compensation and is common for publicly traded companies. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• Stock sales by executives to cover tax obligations are a common practice across the industry.
• The sale is consistent with standard procedures for handling equity compensation.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Protara Therapeutics, insider trading, stock sale, Form 4, executive compensation, equity, TARA, Jacqueline Zummo